Lung Cancer Awareness Month is National ReminderWASHINGTON, Nov. 2, 2012 /PRNewswire-USNewswire/ -- Lung cancer survivors from across the nation have joined together through LUNGevity Foundation to share their stories and educate the public about lung cancer, the nation's number one cancer killer that affects one in 14 Americans. The survivors demonstrate the hope that science offers for more effective lung cancer treatments and the importance of early detection. Throughout the year, but especially during November, national Lung Cancer Awareness Month, those touched by lung cancer seek to build public awareness of the disease and the need for critical research funds. LUNGevity Foundation, the nation's largest lung cancer- focused nonprofit, funds the most promising research for the early detection and successful treatment of lung cancer, and provides information, resources and a community to patients and caregivers. "Progress in lung cancer research is giving us reason to be hopeful," said LUNGevity Foundation President Andrea Stern Ferris. "During Lung Cancer Awareness Month, and throughout the year, creating greater awareness and visibility of the disease is critical. Despite being the nation's number one cancer killer, lung cancer receives relatively little government research funding, and LUNGevity is working to fill this gap. As our spokespeople reflect, anyone can be affected by lung cancer, regardless of age, race, ethnicity or smoking history. I hope their stories help people understand both the impact of lung cancer and the need for investing in science to help those affected." The past decade has seen significant research-based advances in early detection and therapeutics for lung cancer patients. The 2011 National Cancer Institute's National Lung Screening Trial showed the importance of detecting lung cancer early, and for the first time established a screening approach for a high-risk population. Progress is being made in research for the development of blood biomarkers, genome sequencing capabilities and molecular and imaging technologies to help detect the disease. Targeted therapies are greatly improving the treatment experience, including quality of life, for some lung cancer patients, and progress is being made in both immunotherapy and antiangiogenic therapy (cutting off the blood supply to lung cancer tumors).